News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inhibox Ltd. Announces Scopius-5 - the First 100 Million+ Compound 3D Drug Candidate Design Database



12/17/2010 9:41:49 AM

Oxford, UK, December 17, 2010 - InhibOx Ltd, the specialist in novel and effective computational methods for drug discovery, today announces the launch of Scopius-5 - the world's largest currently available drug discovery screening database and the first system to pass 100 million compounds. Scopius-5 is a unique and powerful resource that will enable new levels of innovation and rigor to screening processes in drug discovery.

The Scopius-5 database platform stores many details of selected compounds, invaluable to those working in drug discovery. They include: multiple-conformation 3D models, shape and charge descriptors, property values and compound availability information, and/or synthetic route details. To ensure their usefulness in discovery projects, entries are filtered against a set of drug-likeness criteria - structural and physical properties known to be common to almost all pharmaceutical compounds.

Scopius-5 is the result of almost ten years research and investment by InhibOx, aimed to meet the needs of the pharmaceutical and biotech markets for a large, high-value, specialist database to support computer-aided drug discovery processes. Traditional high-throughput screening (HTS) has proved to be too hit-and-miss, too often; a USD 2 billion industry, which sees an average USD 1 million spend per project (1), with a less than 50 per cent success rate (2) at finding active leads. Its computational equivalent, virtual screening, if well-designed, should dramatically improve both the costs and hit rates, but too often fails because the data sets used are too restricted in the scope of their chemistry, being based on previous projects, covering different, narrow chemistry requirements. Scopius addresses this problem head on by providing true depth and diversity in its chemistry.

Scopius-5 consists of more than 110 million entries in three distinct sections, each enabling different approaches to lead identification and optimization studies:

- Scopius-CSpace: 8.5 million compounds available for immediate ordering and use in screening processes, enabling projects to be kick-started quickly by testing initial hypotheses. More than 5.4 million of these pass InhibOx's filters for traditional drug-likeness.

- Scopius-VSpace: 102 million readily accessible compounds, created in simple 1- or 2-step synthetic processes using well-validated, documented chemistries from starting points in Scopius-CSpace. All entries are fully curated and pass InhibOx's filters for drug-likeness. Scopius-VSpace is thus a rich source of new ideas and potential leads in discovery processes.

- Scopius-FSpace: An extensive library of 3D fragment models, extracted in tightly-defined fragmentation processes from the available compounds in Scopius-CSpace, with vectors defined to support fragment-based design studies, using InhibOx's LOx suite.

Scopius-5 is able to support very large-scale virtual screening studies at practical speeds because each of the 4 billion conformations present in the database is associated with pre-calculated 3D shape and charge descriptors keys, all stored in the efficient Scopius Molecular Key Format (SMKF). This proprietary technology enables ligand molecular comparisons on the basis of 3D shape and electrostatic charge distribution at speeds thousands of times faster than traditional methods, using InhibOx's unique Fast Molecular Hyperspace Comparison (FMHC) approaches. InhibOx's investment in developing these methods and building this huge, carefully curated database has thus delivered a screening capability far beyond the scope of other systems. The company is now actively involved in projects to extend the proprietary Scopius technology and fast search capabilities to clients' in-house data collections.

“InhibOx has developed Scopius-5 platform with associated fast searching technology giving unique capabilities that will allow innovative computer-aided drug discovery services to biotech research operations and support the work of in-house modeling teams in the pharmaceutical sector,” said Paul Davie, CEO of InhibOx. “The lack of a well-curated, high value and searchable database of diverse drug candidate molecules has held-back the success of virtual screening and fragment-based design approaches for many years. The innovations at InhibOx, and the advent of cloud computing to support truly large-scale studies, look set to improve dramatically the effectiveness of these disciplines.”

InhibOx continues to research new discovery methodologies to gain further value from Scopius-5, through its collaborations with several leading academic groups and strategic partners in Europe and the USA. One particular focus, in conjunction with the Cambridge Crystallographic Data Centre, is to extend the fast searching methodology across their protein structure databases to enable the efficient and accurate selectivity studies. Announcements on this project are expected in 2011.

(1) Industrialization of Drug Discovery - Jeffrey S. Handen Ph.D (Ed.), CRC Press, 2005

(2) Chemogenomics in Drug Discovery, Methods and Principles in Medicinal Chemistry Vol. 22

About InhibOx

InhibOx, based in Oxford, UK and Princeton, NJ, delivers novel and effective computational methods for drug discovery to improve the productivity of lead and candidate identification and optimization, through consultancy and software-as-a-service channels. The company is a pioneer in the application of cloud computing to drive very large scale computation at high accuracy, bringing rigorous full-spectrum computational drug discovery processes to bear in pharmaceutical and biotech research. InhibOx was founded by Professor W. Graham Richards, former Chairman of Chemistry at the University of Oxford and world-leading computational chemist. The company grew from the outstandingly successful Screensaver Lifesaver project which involved some 3.5 million personal computers in over 200 countries: the world's biggest computational chemistry experiment finding lead compounds to inhibit cancer targets, anthrax and smallpox. Since then, InhibOx has built up a proprietary technology platform in computer-aided drug design, funded by VCs, private investors, Oxford University and EU research grants. Ongoing activities comprise the development of entirely novel computational drug discovery methods; building Scopius, the world's largest curated database of 3D structures and properties, and their delivery to the life science industries.

Lynne Chapman

ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES